GEN Exclusives

More »

GEN News Highlights

More »
Mar 29, 2010

Helmholtz Zentrum München and Sirion Biotech Partner to Study Lentiviruses in Lymphoma

  • Helmholtz Zentrum München and Sirion Biotech are allying to develop new therapeutic approaches against lymphoid tumors. With a two-year €500,000 grant (about $672,369) from the Federal Ministry for Economics and Technology, the partners will seek to further lentiviral vector systems to better understand the disease mechanisms of this cancer form and to create new treatments.

    Helmholtz Zentrum München and Sirion Biotech seek to optimize the use of lentiviruses as gene vectors for hematopoietic cells. “We want to specifically refine the lentiviral vectors to target the tumor cell markers,” explains Nataša Anastasov, who is in charge of the project at the Institute of Radiation Biology of Helmholtz Zentrum München.

    To achieve this the researchers will first develop new cell lines with improved binding characteristics for virus production. Sirion Biotech, founded in 2006, focuses on producing genetically modified cells and providing technology related to viral vector systems.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?